| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2014-08-28 | UCB (Belgium) Biotie Therapies (Finland) | tozadenant (SYN115) | Parkinson's disease | licensing |
Neurodegenerative diseases - CNS diseases | Licensing agreement |
| 2014-08-28 | Roche (Switzerland) Chugai Pharmaceutical (Japan) | Licensing agreement | ||||
| 2014-08-27 | Definigen (UK) European Bank for Induced Pluripotent Stem Cells (EBiSC) Consortium | cell bank for human iPS cells | collaboration |
Regenerative medicine | Collaboration agreement | |
| 2014-08-26 | Bavarian Nordic (Denmark) Canadian Government (Canada) | Imvamune® smallpox vaccine | smallpox | services |
Infectious diseases | Services contract |
| 2014-08-26 | Biogen Idec (USA - MA) | Neurodegenerative diseases | Nomination | |||
| 2014-08-26 | Nordic Nanovector (Norway) | Nomination | ||||
| 2014-08-25 | Cardiome Pharma (Canada) Eurolab Especialidades Medicinales de Eurofar (Argentina) | Brinavess™ (vernakalant intravenous) | rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults for non-surgery patients with atrial fibrillation of seven days duration or less and for post-cardiac surgery patients with atrial fibrillation of three days duration or less | distribution |
Cardiovascular diseases | Distribution agreement |
| 2014-08-25 | MRC Technology (UK) Bio-Techne (USA - MN) | Genetically encoded Orthogonal Protection and Activated Ligation (GOPAL - protein synthesis technology) | licensing |
Technology - Services | Licensing agreement | |
| 2014-08-21 | GSK (UK) Pozen (USA - NC) Pernix Therapeutics (USA - SC) | Treximet® (sumatriptan / naproxen sodium) | migraine attacks | sale |
CNS diseases | Product acquisition |
| 2014-08-21 | Illumina (USA - CA) AstraZeneca (UK) Janssen Biotech, a J&J company (USA - NJ) Sanofi (France) | universal next-generation sequencing (NGS)-based oncology test system | cancers | Cancer - Oncology | Collaboration agreement | |
| 2014-08-21 | BiogenIdec (USA - MA) | Nomination | ||||
| 2014-08-21 | Covidien (Ireland) | Pipeline and Alligator™ retrieval devices | Cardiovascular diseases | Validation of a production plant | ||
| 2014-08-21 | Sarepta Therapeutics (USA - MA) Flagship Biosciences (USA - CO) | automated quantitative endpoint measurements | Duchenne muscular dystrophy | development |
Genetic diseases - Neuromuscular diseases - Rare diseases | Development agreement |
| 2014-08-21 | Antitope, an Abzena\'s subsidiary (UK) University College London (UCL) (UK) | fully humanized antibodies using Antitope’s Composite Human Antibody™ technology including a humanized anti-LRG1 antibody | ophtalmological diseases | R&D licensing |
Ophtalmological diseases | R&D agreement |
| 2014-08-21 | Janssen R&D, a J&J company (USA - NJ) - ViaCyte (USA - CA) | VC-01™ combination product | type 1 diabetes | Metabolic diseases - Regenerative medicine | Licensing agreement | |
| 2014-08-21 | Acrux (Australia) Hexima (Australia) | medical product to treat fungal infections | fungal diseases | termination of an agreement |
Infectious diseases | Termination of an agreement |
| 2014-08-20 | Novartis (Switzerland) Global Alliance for TB Drug Development (TB Alliance) | indolcarboxamides including NITD304 | tuberculosis | licensing agreement |
Infectious diseases | Licensing agreement |
| 2014-08-20 | AstraZeneca (UK) Mitsubishi Tanabe Pharma Corporation (Japan) | diabetic nephropathy | R&D agreement |
Metabolic diseases - Renal diseases - Kidney diseases | R&D agreement | |
| 2014-08-20 | The University of Nottingham (UK) China Resources Pharmaceutical Group (CRPG) (China) | Collaboration agreement | ||||
| 2014-08-20 | BMS (USA - NY) Celgene (USA - NJ) | Opdivo® (nivolumab) and Abraxane® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) | multiple tumor types including HER-2 negative metastatic breast cancer, pancreatic cancer and non-small cell lung cancer (NSCLC) | Cancer - Oncology | Clinical research agreement |
